Cardinal Health Completes Biotech Purchase

Cardinal Health has agreed to acquire the assets of Biotech, an operator of Positron Emission Tomography (PET) cyclotrons and nuclear pharmacies in the Southwestern United States, according to the Dublin, Ohio-based firm.

Cardinal Health owns and operates nearly 160 nuclear pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. These facilities are registered with the U.S. Food and Drug Administration (FDA) to manufacture PET imaging agents that are used by physicians to diagnose various medical conditions.

With the acquision, Cardinal Health will expand its existing U.S. PET business with Biotech’s facilities in Arizona, Nevada, New Mexico and Texas.

In addition to the manufacturing and distribution of fluorodeoxyglucose (FDG)-based PET agents, Cardinal Health recently opened its network to support clinical trials of new and novel PET agents to advance the future of molecular imaging.

“The Biotech acquisition helps demonstrate Cardinal Health’s commitment to advancing the future of molecular imaging, accelerates the build-out of our PET business and augments our leading network of nuclear pharmacies,” said John Rademacher, president and general manager of Nuclear and Specialty Pharmacy Services for Cardinal Health. “In addition to their facilities across the Southwestern U.S., Biotech’s highly skilled employees and their intellectual property will be immediately applicable tosupport our expanding role in supporting new drug development.”